Vivos Therapeutics (VVOS)
(Delayed Data from NSDQ)
$3.44 USD
+0.10 (2.99%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.44 0.00 (0.00%) 6:34 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Vivos Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
VVOS 3.44 +0.10(2.99%)
Will VVOS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VVOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VVOS
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
VVOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for VVOS
VVOS falls 5.11% on September 19, leaving the technical picture intact
Bullish Engulfing appears for VVOS after 3.53% move
Vivos Therapeutics (VVOS) Achieves Milestone in Pediatric Sleep Apnea Treatment
Vivos Therapeutics announces trial results in pediatric OSA treatment
Vivos Therapeutics announces trial results in pediatric OSA treatment